Engineered TILs/CAR-TILs to Treat Advanced Solid Tumors

Tumor infiltration lymphocytes (TILs) have been harvested from advanced cancer patients and constructed to knockout PD1 gene and express scFvs against both PD1 and CTALA4 and CARs against various antigens, followed by transfusion into the patients. The safety, tolerance, and preliminary clinical efficacy of the TILs will be evaluated.

Trial Details

NCT ID

NCT04842812

Phase

PHASE1

Sponsor

Second Affiliated Hospital of Guangzhou Medical University

Status

RECRUITING

Cancer Type

Liver Cancer

Interventions

TILs and CAR-TILs targeting HER2, Mesothelin, PSCA, MUC1, Lewis-Y, GPC3, AXL, EGFR, Claudin18.2/6, ROR1, GD1, or B7-H3

Locations (sample)

Guangzhou, China|23.11667,113.25

Key Eligibility Criteria

Patients with advanced cancers that failed to current available therapies;
Life expectancy \>12 weeks;
Adequate heart, lung, liver, kidney functions;
Available for tumor biopsy or cancerous effusions;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liver Cancer Trials on Trialify →